In this study, we stressed that some tumour types with abnormalities involving the PI3K/AKT/mTOR pathway or with sustained antiangiogenic activity such as kidney cancers are highly sensitive to mTORC1 inhibitors. This evidence concerns the gene AKT1 and neoplasm.